[Thrombotic thrombocytopenic purpura]

Area of Science:

• Hematology
• Internal Medicine
• Pharmacology

Background:

• Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy characterized by hemolytic anemia and thrombocytopenia.
• Distinguishing TTP from other conditions like hemolytic uremic syndrome (HUS) is challenging based solely on clinical presentation.
• Accurate diagnosis of TTP necessitates measuring ADAMTS13 activity, with levels below 10% being a key indicator.

Purpose of the Study:

• To review the current landscape of molecular targeted therapies for thrombotic thrombocytopenic purpura (TTP).
• To highlight recent advancements and future therapeutic expectations in TTP management.
• To discuss the diagnostic significance of ADAMTS13 activity testing in TTP.

Main Methods:

• Literature review focusing on molecular targeted therapies for TTP.
• Analysis of diagnostic criteria and therapeutic advancements in TTP.
• Discussion of approved and investigational treatments for TTP.

Main Results:

• TTP is classified as an intractable disease, leading to approved clinical applications of ADAMTS13 testing and rituximab in Japan.
• Current therapeutic strategies for TTP involve targeting the underlying mechanisms of the disease.
• Emerging treatments, including recombinant ADAMTS13 and caplacizumab, show promise for immune-mediated TTP.

Conclusions:

• Molecular targeted therapy represents a significant advancement in managing TTP.
• Accurate diagnosis via ADAMTS13 activity testing is crucial for appropriate treatment selection.
• The development of novel therapies like recombinant ADAMTS13 and caplacizumab offers improved outcomes for TTP patients, particularly those with immune-mediated forms.